User:Mr. Ibrahem/Cetirizine
Clinical data | |
---|---|
Pronunciation | /sɛˈtɪrɪziːn/ |
Trade names | Zyrtec, Incidal, others |
AHFS/Drugs.com | Systemic: Monograph Eye: Monograph |
MedlinePlus | a698026 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Second-generation antihistamine |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Well-absorbed (>70%)[1] |
Protein binding | 88–96%[1] |
Metabolism | Minimal (non-cytochrome P450-mediated)[3][2] |
Onset of action | 20–42 minutes[2] |
Elimination half-life | Mean: 8.3 hours[3][2] Range: 6.5–10 hours[4] |
Duration of action | ≥24 hours[4] |
Excretion | Urine: 70–85%[3] Feces: 10–13%[3] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H25ClN2O3 |
Molar mass | 388.89 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Cetirizine, sold under the brand name Zyrtec among others, is an antihistamine used to treat allergic rhinitis (hay fever), dermatitis, and urticaria.[6] It is taken by mouth.[7] Effects generally begin within an hour and last for about a day.[7] The degree of benefit is similar to other antihistamines such as diphenhydramine.[7]
Common side effects include sleepiness, dry mouth, headache, and abdominal pain.[7] The degree of sleepiness that occurs is generally less than with first generation antihistamines.[6] Serious side effects may include aggression and angioedema.[6] Use in pregnancy appears safe, but use during breastfeeding is not recommended.[8] It is a second-generation antihistamine and works by blocking histamine H1 receptors, mostly outside the brain.[7]
It was patented in 1981 and came into medical use in 1987.[9] It is available as a generic medication.[6] A month's supply in the United Kingdom costs the NHS about £0.70 as of 2019.[6] In the United States the wholesale cost of this amount is about US$2.50.[10] In 2017, it was the 66th most commonly prescribed medication in the United States, with more than eleven million prescriptions.[11][12]
References[edit]
- ^ a b Chen C (2008). "Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine". Curr. Med. Chem. 15 (21): 2173–91. doi:10.2174/092986708785747625. PMID 18781943.
- ^ a b c Simons FE, Simons KJ (1999). "Clinical pharmacology of new histamine H1 receptor antagonists". Clin Pharmacokinet. 36 (5): 329–52. doi:10.2165/00003088-199936050-00003. PMID 10384858.
- ^ a b c d Portnoy JM, Dinakar C (2004). "Review of cetirizine hydrochloride for the treatment of allergic disorders". Expert Opin Pharmacother. 5 (1): 125–35. doi:10.1517/14656566.5.1.125. PMID 14680442.
- ^ a b Simons FE (2002). "Comparative pharmacology of H1 antihistamines: clinical relevance". Am. J. Med. 113 Suppl 9A (9): 38S–46S. doi:10.1016/s0002-9343(02)01436-5. PMID 12517581.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 7 September 2020.
- ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 279. ISBN 9780857113382.
- ^ a b c d e "Cetirizine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Cetirizine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Cetirizine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.